Bi-Specific 3rd Generation CAR T therapy is a revolutionary advancement in cellular immunotherapy, primarily used to treat ...

The rate of cGVHD-free survival was 78% at 1 year in patients who received Orca-T compared with 38% among patients who ...

For the 80 million people worldwide with celiac disease, the only treatment available is to cut grains like pasta and bread out of their lives. | For the 80 million people worldwide who have celiac ...

Among the 13 CAR-T therapeutics that have received regulatory approval are Gilead’s Yescarta and Immuneel Therapeutics’ ...

LUND, SE / ACCESS Newswire / March 20, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class i ...

In an early-stage clinical trial, the therapy nearly doubled the expected survival time of young patients. Still, experts ...

Targeted inhibition of a "signal jammer" protein may improve how tumors respond to immunotherapy. Published today in Nature, a new study demonstrates how some cancer cells use the protein ...

After 10 years of efforts, a Lenexa company won regulatory approval for a new type of treatment for cancer in dogs.

ELIAS Animal Health, a companion animal cancer therapeutics company, shared today that the USDA Center for Veterinary ...

Fruzaqla given in combination with sintilimab slowed progression in the second line for those with locally advanced or metastatic renal cell carcinoma.

Orca Bio has shared promising results from a late-stage study of its investigational allogeneic T-cell immunotherapy in ...